ARTICLE | Company News
Adimab, Arsanis deal
March 10, 2017 7:38 PM UTC
Adimab granted Arsanis exclusive, worldwide rights to antibodies against respiratory syncytial virus (RSV). Adimab is eligible to receive undisclosed license fees, development milestones and royalties...